To announce the FDA approval of a new inhaled therapy for asthma maintenance treatment.
Approach:
Key Findings:
Significant improvement in forced expiratory volume within 3 hours at 24 weeks.
Improvements in trough lung function over 12 to 24 weeks.
No new safety or tolerability concerns identified.
Interpretation:
The approval of Breztri addresses the needs of asthma patients who remain uncontrolled on dual therapies, potentially reducing exacerbations and improving daily breathing.
Limitations:
Not intended for acute bronchospasm relief or as a substitute for rescue inhalers.
Limited to patients aged 12 years and older.
Conclusion:
Breztri offers a new maintenance treatment option for asthma, expanding its use beyond chronic obstructive pulmonary disease.
